TP53 and gastrointestinal stromal tumor: In a phase III study of advanced/metastatic GIST patients undergoing imatinib 400 mg vs 800 mg daily treatment, 353 GISTs were screened for p53 immunostaining, and only samples with high p53 expression were subsequently analyzed for TP53 mutations (42).